CBGA - what is it and why is it called the "mother molecule" of cannabinoids?

CBD, CBG and THC are now known even to people who are just starting to get interested in cannabinoids. However, there is another important compound in the hemp plant - CBGA (cannabigerolic acid). It is from it that the precursors of several of the most well-known cannabinoids are formed during the development of the plant. Because of this feature, CBGA is often called the “mother molecule” of cannabinoids.

Interest in cannabigerolic acid has grown significantly in recent years. Researchers are studying its biological activity, interaction with cellular mechanisms, and potential applications. At the same time, CBGA remains a much less studied substance than CBD, and much of the available results have been obtained in laboratory and preclinical experiments.

What is CBGA?

CBGA, or cannabigerolic acid, is a natural cannabinoid acid produced in the Cannabis plant. Its uniqueness lies not only in its own properties, but also in its central role in the biosynthesis of other cannabinoids.

In the plant, CBGA is formed from olivetolic acid and geranyl pyrophosphate. Special enzymes then use it as a kind of starting material for the formation of other cannabinoid acids.

Why is CBGA called the “mother molecule”?

It is from CBGA that THCA, CBDA, and CBCA can be formed—the acidic precursors of THC, CBD, and CBC, respectively. The direction of the transformation depends on the activity of enzymes in the plant.

In simplified terms, this process can be represented as follows:

• CBGA → CBDA → CBD after the corresponding biochemical transformations;
• CBGA → THCA → THC;
• CBGA → CBCA → CBC.

This is why cannabigerolic acid holds a special place in the chemistry of cannabis. As the plant matures, a significant portion of CBGA is converted to other cannabinoid acids, so its final concentration can be relatively low.

Are CBGA and CBG the same thing?

No. CBGA and CBG are related but different compounds. The “A” in CBGA refers to the acid form. When exposed to heat or over time, decarboxylation occurs: the molecule loses its carboxyl group, and CBGA is converted to CBG.

A similar principle applies to other cannabinoids: CBDA is the precursor to CBD, and THCA is the precursor to THC. Therefore, when evaluating the composition of an extract, it is important to distinguish between neutral cannabinoids and their acidic forms.

How does CBGA interact with the body?

The pharmacological profile of cannabigerolic acid is still being studied. Studies show that CBGA does not interact strongly with the classical cannabinoid receptors CB1 and CB2. Instead, other molecular targets are attracting the attention of scientists.

One area of focus is the TRPM7 ion channel, which is involved in the regulation of cellular processes and the metabolism of magnesium and calcium. In preclinical studies, CBGA has been shown to affect the activity of this channel.

This is an interesting discovery for basic science, but it should not automatically be interpreted as proof of the therapeutic efficacy of CBGA in humans.

What does science say about the properties of CBGA?

One of the most actively researched areas is the relationship between cannabigerolic acid and inflammation and oxidative stress. In cell experiments and animal models, scientists have observed changes in some inflammatory markers after CBGA administration.

Some preclinical studies have focused on the effects of the substance on kidney tissue. In mouse models, the effect of CBGA on cisplatin-induced damage was investigated. The results were interesting enough to further study the mechanisms associated with TRPM7, oxidative stress, and fibrosis.

The key word here is “preclinical.” The results of an experiment in cells or laboratory animals do not mean that a substance will have the same effect in humans.

CBGA and skin: a new area of research

Another promising area is dermatology. In laboratory experiments, researchers evaluated the effects of minor cannabinoids on skin cells and markers of inflammatory response.

CBGA has demonstrated activity on a number of signaling mechanisms, including those related to TRPV1 and MAPK. These results provide a basis for further investigation of cannabigerolic acid as a component of cosmetic and dermatological formulas.

However, it is premature to say that CBGA has been proven to treat psoriasis, dermatitis, eczema, or other skin conditions. This requires high-quality clinical trials involving humans.

CBGA, CBD and CBG: What's the difference?

Why is CBGA still less common than CBD?

CBD has already become one of the most well-known cannabinoids and is used in a wide range of products. CBGA is a more niche substance. This is partly due to the biology of the plant itself: a significant amount of cannabigerolic acid is converted into other compounds during the development of cannabis.

Obtaining standardized raw materials with high CBGA content requires appropriate plant selection, extraction techniques, and laboratory control. It is also important for research to accurately determine the concentration and purity of the substance used.

What is known about the safety of CBGA?

This is where one of the biggest gaps remains. Data on the long-term use of CBGA in humans is still lacking. Bioavailability, metabolism, optimal routes of administration, and potential drug interactions also require further study.

Therefore, the statement about the “complete safety” of cannabigerolic acid today would be incorrect. The natural origin of the substance does not in itself guarantee the absence of adverse reactions or interactions.

The Future of CBGA: Why Do Scientists Continue Research?

CBGA is interesting for two reasons. First, it is impossible to fully understand the process of formation of the main cannabinoids in cannabis without it. Second, early studies demonstrate that this molecule has its own biological activity, which may be different from the properties of CBD or CBG.

The next important step is to conduct standardized studies and clinical trials in humans, which should help determine the pharmacokinetics of CBGA, its true bioavailability, long-term safety, and areas where the compound could actually be of practical value.

CBGA is one of the fundamental components of the cannabinoid profile of cannabis. It is called the “mother molecule” because it acts as the starting compound for the formation of CBDA, THCA, and CBCA, and through them, CBD, THC, and CBC.

Cannabigerolic acid is currently attracting increasing attention from researchers, but the scientific basis for it is still in its early stages. For the Effectplants blog, it is important to distinguish between promising laboratory results and clinically proven properties: CBGA has interesting potential, but most of its possible applications still need to be tested in humans.

Not a medical recommendation. Cannabinoid products should not be used to self-treat medical conditions or replace medically prescribed therapy.